Functional, Metabolic and Morphologic Results of Ex Vivo Donor Lung Perfusion with a Perfluorocarbon-Based Oxygen Carrier Nanoemulsion in a Large Animal Transplantation Model.
ex vivo lung perfusion
lung transplantation
oxygen carrier
perfluorocarbon
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
received:
01
10
2020
revised:
06
11
2020
accepted:
09
11
2020
entrez:
21
11
2020
pubmed:
22
11
2020
medline:
9
7
2021
Statut:
epublish
Résumé
Ex vivo lung perfusion (EVLP) is a technology that allows the re-evaluation of questionable donor lung before implantation and it has the potential to repair injured donor lungs that are otherwise unsuitable for transplantation. We hypothesized that perfluorocarbon-based oxygen carrier, a novel reconditioning strategy instilled during EVLP would improve graft function. We utilized perfluorocarbon-based oxygen carrier (PFCOC) during EVLP to recondition and improve lung graft function in a pig model of EVLP and lung transplantation. Lungs were retrieved and stored for 24 h at 4 °C. EVLP was done for 6 h with or without PFCOC. In the transplantation groups, left lung transplantation was done after EVLP with or without PFCOC. Allograft function was assessed by means of pulmonary gas exchange, lung mechanics and vascular pressures, histology and transmission electron microscopy (TEM). In the EVLP only groups, physiological and biochemical markers during the 6-h perfusion period were comparable. However, perfusate lactate potassium levels were lower and ATP levels were higher in the PFCOC group. Radiologic assessment revealed significantly more lung infiltrates in the controls than in the PFCOC group ( PFCOC application is safe during EVLP in lungs preserved 24 h at 4 °C. Although this strategy did not significantly affect the EVLP physiology, metabolic markers of the donor quality such as lactate production, glucose consumption, neutrophil infiltration and preservation of mitochondrial function were better in the PFCOC group. Following transplantation, PFCOC resulted in better graft function and TEM showed better tissue preservation, cellular viability and improved gas transport.
Sections du résumé
BACKGROUND
Ex vivo lung perfusion (EVLP) is a technology that allows the re-evaluation of questionable donor lung before implantation and it has the potential to repair injured donor lungs that are otherwise unsuitable for transplantation. We hypothesized that perfluorocarbon-based oxygen carrier, a novel reconditioning strategy instilled during EVLP would improve graft function.
METHODS
We utilized perfluorocarbon-based oxygen carrier (PFCOC) during EVLP to recondition and improve lung graft function in a pig model of EVLP and lung transplantation. Lungs were retrieved and stored for 24 h at 4 °C. EVLP was done for 6 h with or without PFCOC. In the transplantation groups, left lung transplantation was done after EVLP with or without PFCOC. Allograft function was assessed by means of pulmonary gas exchange, lung mechanics and vascular pressures, histology and transmission electron microscopy (TEM).
RESULTS
In the EVLP only groups, physiological and biochemical markers during the 6-h perfusion period were comparable. However, perfusate lactate potassium levels were lower and ATP levels were higher in the PFCOC group. Radiologic assessment revealed significantly more lung infiltrates in the controls than in the PFCOC group (
CONCLUSION
PFCOC application is safe during EVLP in lungs preserved 24 h at 4 °C. Although this strategy did not significantly affect the EVLP physiology, metabolic markers of the donor quality such as lactate production, glucose consumption, neutrophil infiltration and preservation of mitochondrial function were better in the PFCOC group. Following transplantation, PFCOC resulted in better graft function and TEM showed better tissue preservation, cellular viability and improved gas transport.
Identifiants
pubmed: 33218154
pii: cells9112501
doi: 10.3390/cells9112501
pmc: PMC7698917
pii:
doi:
Substances chimiques
Fluorocarbons
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Vasc Interv Radiol. 2012 Jan;23(1):116-21
pubmed: 22079515
Antioxid Redox Signal. 2019 Sep 20;31(9):608-622
pubmed: 31037949
Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):819-30
pubmed: 1391516
Nat Commun. 2019 Jan 29;10(1):481
pubmed: 30696822
J Surg Res. 2013 Oct;184(2):1143-9
pubmed: 23706563
Brain Res. 2016 Mar 1;1634:132-139
pubmed: 26794250
Transplant Proc. 2011 May;43(4):993-6
pubmed: 21620034
Am J Transplant. 2010 Apr;10(4 Pt 2):1047-68
pubmed: 20420652
Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H704-H715
pubmed: 29127235
J Thorac Cardiovasc Surg. 1999 Aug;118(2):369-70
pubmed: 10425014
Am J Respir Crit Care Med. 2016 Mar 15;193(6):605-6
pubmed: 26977969
Crit Care Clin. 1987 Oct;3(4):725-46
pubmed: 3332221
Semin Thorac Cardiovasc Surg. 2004 Winter;16(4):309-21
pubmed: 15635535
J Surg Res. 2017 Oct;218:341-347
pubmed: 28985871
Crit Care Med. 1995 Sep;23(9):1533-9
pubmed: 7664556
Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):1045-9
pubmed: 1391425
Transpl Int. 2015 Jun;28(6):643-56
pubmed: 24629039
N Engl J Med. 2011 Apr 14;364(15):1431-40
pubmed: 21488765
Ann Thorac Surg. 2004 Feb;77(2):438-44; discussion 444
pubmed: 14759412
N Engl J Med. 1996 Sep 12;335(11):761-7
pubmed: 8778584
Transfusion. 1998 Feb;38(2):145-55
pubmed: 9531945
Inflammation. 2013 Dec;36(6):1383-92
pubmed: 23807052
Anesthesiology. 1999 Nov;91(5):1195-208
pubmed: 10551568
Lancet. 2001 Mar 17;357(9259):825-9
pubmed: 11265950
PLoS One. 2014 Jan 28;9(1):e87826
pubmed: 24489970
J Heart Lung Transplant. 2008 Dec;27(12):1319-25
pubmed: 19059112
J Heart Lung Transplant. 2007 Oct;26(10):1054-60
pubmed: 17919627
J Heart Lung Transplant. 2019 Dec;38(12):1235-1245
pubmed: 31777330
Anesthesiology. 2002 Dec;97(6):1338-49
pubmed: 12459658
J Heart Lung Transplant. 2011 Dec;30(12):1312-9
pubmed: 21930395
Adv Mater. 2018 Dec;30(49):e1804693
pubmed: 30294884
J Funct Biomater. 2016 Nov 18;7(4):
pubmed: 27869709
Biomaterials. 1998 Aug;19(16):1529-39
pubmed: 9794531
J Thorac Dis. 2017 Aug;9(8):2660-2669
pubmed: 28932573
Science. 1966 Jun 24;152(3730):1755-6
pubmed: 5938414
Annu Rev Biochem. 2013;82:551-75
pubmed: 23527692
Front Biosci (Landmark Ed). 2009 Jan 01;14:665-88
pubmed: 19273094
Eur J Cardiothorac Surg. 2017 Jul 1;52(1):171-177
pubmed: 28874022
ASAIO J. 2013 Jul-Aug;59(4):337-54
pubmed: 23820271
World J Surg. 2001 Feb;25(2):244-50
pubmed: 11338028
Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):43-52
pubmed: 9083625
Crit Care Med. 2000 Feb;28(2):479-83
pubmed: 10708187
Intensive Care Med. 2005 Jul;31(7):977-84
pubmed: 15931525
J Heart Lung Transplant. 2008 Sep;27(9):1016-22
pubmed: 18765195
Transplantation. 2013 Sep;96(6):509-18
pubmed: 23694953
Hum Gene Ther. 2017 Sep;28(9):757-765
pubmed: 28052693
J Heart Lung Transplant. 2005 Sep;24(9):1369-77
pubmed: 16143259
Ann Surg. 2019 Nov;270(5):783-790
pubmed: 31592808
Artif Organs. 2010 Aug;34(8):622-34
pubmed: 20698841
Am J Transplant. 2015 Jan;15 Suppl 2:1-28
pubmed: 25626342
J Thorac Cardiovasc Surg. 1995 Sep;110(3):774-85
pubmed: 7564446
J Heart Lung Transplant. 2005 Jan;24(1):20-8
pubmed: 15653374
J Heart Lung Transplant. 2012 Oct;31(10):1120-6
pubmed: 22975103
Anesthesiology. 2003 Jun;98(6):1391-9
pubmed: 12766648
J Heart Lung Transplant. 2019 Nov;38(11):1214-1223
pubmed: 31474491
Transl Stroke Res. 2019 Oct;10(5):583-595
pubmed: 30506268
J Heart Lung Transplant. 2017 May 20;:
pubmed: 28587802
Transplant Direct. 2020 Aug 21;6(9):e600
pubmed: 32904032
J Heart Lung Transplant. 2003 Nov;22(11):1226-33
pubmed: 14585384
J Heart Lung Transplant. 2008 Nov;27(11):1229-36
pubmed: 18971096
Ann Thorac Surg. 2003 Jul;76(1):244-52; discussion 252
pubmed: 12842550
Chem Rev. 2001 Sep;101(9):2797-920
pubmed: 11749396
J Neurosurg Spine. 2008 Aug;9(2):213-20
pubmed: 18764757
Transplantation. 2019 Feb;103(2):233-234
pubmed: 30422951
Shock. 2003 Nov;20(5):449-57
pubmed: 14560110
PLoS One. 2008 Apr 23;3(4):e2010
pubmed: 18431491
Neonatology. 2007;91(2):127-33
pubmed: 17344663
Liver Transpl. 2017 Sep;23(9):1171-1185
pubmed: 28650112
Soft Matter. 2015 Aug 14;11(30):5982-94
pubmed: 26110877
Am J Transplant. 2009 Oct;9(10):2262-9
pubmed: 19663886
J Surg Res. 2007 Mar;138(1):135-40
pubmed: 17173933
Sci Transl Med. 2009 Oct 28;1(4):4ra9
pubmed: 20368171
Ann Thorac Surg. 2016 Dec;102(6):1845-1853
pubmed: 27614736
Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1043-54
pubmed: 7849908
Adv Exp Med Biol. 1994;345:227-34
pubmed: 8079712
Ann Surg. 2003 Dec;238(6):782-92; discussion 792-3
pubmed: 14631215
J Thorac Cardiovasc Surg. 2002 Mar;123(3):421-7; discussion, 427-8
pubmed: 11882811
Crit Care Med. 2008 Apr;36(4):1222-9
pubmed: 18379249
Transpl Int. 2011 Jan;24(1):78-84
pubmed: 20723176
Chem Rev. 2009 May;109(5):1714-92
pubmed: 19296687
Chembiochem. 2006 Aug;7(8):1160-3
pubmed: 16927312